Argitalpenak (28) Luis Alberto Marin Rubio argitalpenak

2021

  1. The novel HLA-DQB1*06:03:27 allele characterised by sequence-based typing in a European bone marrow donor

    HLA, Vol. 98, Núm. 5, pp. 498-500

2019

  1. HLA-DQB1*03:01:01:21Q, a novel HLA-DQB1 allele, detected in a Spanish volunteer bone marrow donor

    HLA, Vol. 94, Núm. 4, pp. 393-394

  2. High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing

    Human Immunology, Vol. 80, Núm. 7, pp. 429-436

  3. NKG2D polymorphism in melanoma patients from Southeastern Spain

    Cancers, Vol. 11, Núm. 4

  4. Three new HLA alleles, HLA-A*02:01:01:126, -B*35:01:01:40, and -B*44:02:01:37 detected in Spanish donors

    HLA, Vol. 94, Núm. 6, pp. 514-515

2018

  1. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study

    Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484

2017

  1. A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study

    Thyroid, Vol. 27, Núm. 8, pp. 1058-1067

  2. From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: A whole-exome analysis of abnormalities leading to transformation

    Blood Cancer Journal, Vol. 7, Núm. 8

2016

  1. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma

    Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262

  2. Report From the First and Second Spanish Killer Immunoglobulin-Like Receptor Genotyping Workshops: External Quality Control for Natural Killer Alloreactive Donor Selection in Haploidentical Stem Cell Transplantation

    Transplantation Proceedings

2015

  1. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  2. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  3. Informe del Taller Ibérico de Histocompatibilidad 2013. Componente de análisis de situación de procedimiento de pruebas cruzadas en guardias de trasplante de órganos

    Inmunologia, Vol. 33, Núm. 1, pp. 27-33

2013

  1. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

  2. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

  3. Reunión anual del Grupo Español de trabajo en histocompatibilidad e inmunología del trasplante 2012. Estandarización de informes clínicos de sensibilización por anticuerpos anti-antígeno leucocitario humano

    Inmunologia

  4. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma

    Annals of Hematology, Vol. 92, Núm. 1, pp. 97-100

2012

  1. Evolution of soluble forms of CD86, CD95 and CD95L molecules in liver transplant recipients

    Transplant Immunology, Vol. 26, Núm. 2-3, pp. 94-100

  2. Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: Is the relevance of HLA-A locus matching being underestimated?

    Transplant Immunology, Vol. 26, Núm. 2-3, pp. 88-93